JW Lifescience

At a glance

JW Lifescience filed 26 disclosures in the last 12 months, including 4 5% holder and 3 earnings. The most recent key filing was on Aug 12: Operating profit ₩7.8B, up 3.8% YoY. Revenue ₩56.7B, down 0.8% YoY.

Revenue for 2025 was ₩258B, up 15.9% on 2024. Operating margin was 12.9% against 16.1% a year earlier. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩127B and operating profit of ₩18.7B.

The 2025 annual report lists 319 employees with an average tenure of 9.2 years and average pay of ₩68M, #778 of 2,191 listed companies by average pay. Its 4 directors and auditors were paid ₩67M each on average. It paid ₩550 per common share in cash dividends, against ₩500 a year earlier (+10%). JW홀딩스 and related parties held 43.09% at year end.

Of 4 recent 5%+ holder reports, 4 raised and 0 cut a stake; the largest stake reported was 9.72% on Jul 10.

From the 2025 annual report

Staff: 319 (232 men, 87 women), of whom 30 on fixed-term contracts. Total pay for the year: ₩22.4B. Directors and auditors: 4, paid ₩269M in total.

Dividends (common shares)

Largest shareholder

JW홀딩스 holds 42.98%; with 4 related parties the group holds 43.09% of common shares at year end.

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports